Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) ranks among the best biotech stocks to buy. On September 24, Leerink Partners maintained its Outperform rating on Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) and raised its price target from $63 to$68. The boost comes after topline results for Ionis’ Alexander disease therapy, zilganersen. Using the 10-meter walk test (10MWT), Leerink observed that Zilganersen showed a statistically significant improvement in stabilizing gait speed and steady gains across key seco ...